Page last updated: 2024-12-08

6,7-dimethyl-8-ribityllumazine, (d)-isomer

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

6,7-dimethyl-8-ribityllumazine: RN given refers to unlabeled cpd without isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

6,7-dimethyl-8-(1-D-ribityl)lumazine : The pteridine that is lumazine substituted with methyl groups at C-6 and -7 and with a 1-D-ribityl group on N-8. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID168989
CHEBI ID17601
SCHEMBL ID15603809
SCHEMBL ID21524592
MeSH IDM0307547

Synonyms (45)

Synonym
ribitol, 1-deoxy-1-(3,4-dihydro-6,7-dimethyl-2,4-dioxo-8(2h)-pteridinyl)-
dmdrl
6,7-dimethyl-8-ribityllumazine
6,7-dimethyl-8-(1'-d-ribityl)lumazine
6,7-dimethyl-8-d-ribityllumazine
CHEBI:17601 ,
1-deoxy-1-[6,7-dimethyl-2,4-dioxo-3,4-dihydropteridin-8(2h)-yl]-d-ribitol
rl-6,7-dime
5118-16-1
C04332
6,7-dimethyl-8-(1-d-ribityl)lumazine
6,7-dimethyl-8-(d-ribityl)lumazine
1-deoxy-1-(6,7-dimethyl-2,4-dioxo-3,4-dihydropteridin-8(2h)-yl)-d-ribitol
6,7-dimethyl-8-[(2s,3s,4r)-2,3,4,5-tetrahydroxypentyl]pteridine-2,4-dione
EPITOPE ID:178096
SCHEMBL15603809
2535-20-8
DTXSID90199199
1-deoxy-1-(3,4-dihydro-6,7-dimethyl-2,4-dioxo-8(2h)-pteridinyl)-ribitol
6,7-dimethyl-8-(1'-d-ribityl) lumazine
d-ribitol, 1-deoxy-1-(3,4-dihydro-6,7-dimethyl-2,4-dioxo-8(2h)-pteridinyl)-
2,4(1h,3h)-pteridinedione, 6,7-dimethyl-8-(2,3,4,5-tetrahydroxypentyl)-, (2s-(2r*,3r*,4s*))-
25351-45-5
1-deoxy-1-(3,4-dihydro-6,7-dimethyl-2,4-dioxo-8(2h)-pteridinyl)-d-ribitol
russupteridine iv
riboflavin impurity c [ep impurity]
O1DSD0WC7M ,
6,7-dimethylribolumazine
6,7-dimethylribityllumazine
6,7-dimethyl-8-((2s,3s,4r)-2,3,4,5-tetrahydroxypentyl)pteridine-2,4(3h,8h)-dione
lumazine, 6,7-dimethyl-8-(d-ribo-2,3,4,5-tetrahydroxypentyl)-
Q4641523
6,7-dimethylribityl lumazine
6,7-dimethyl-8-ribitvllumazine
SXDXRJZUAJBNFL-XKSSXDPKSA-N
6,7-dimethyl-8-(1'-d-ribityl)-lumazine
6,7-dimethyl-8-ribityl lumazine
SCHEMBL21524592
unii-o1dsd0wc7m
riboflavin impurity c [ep]
6,7-dimethyl-8-[(2s,3s,4r)-2,3,4,5-tetrahydroxypentyl]-2,3,4,8-tetrahydropteridine-2,4-dione
HY-111661
CS-0089408
PD064070
AKOS040757841
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
cofactorAn organic molecule or ion (usually a metal ion) that is required by an enzyme for its activity. It may be attached either loosely (coenzyme) or tightly (prosthetic group).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
pteridines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Riboflavin, FMN, and FAD biosynthesis04
Flavin biosynthesis221

Research

Studies (50)

TimeframeStudies, This Drug (%)All Drugs %
pre-199021 (42.00)18.7374
1990's3 (6.00)18.2507
2000's15 (30.00)29.6817
2010's11 (22.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.96 (24.57)
Research Supply Index3.97 (2.92)
Research Growth Index4.93 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other52 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]